Pharmaceutical raw materials white powder Peptide Liraglutide

CAS: 204656-20-2

MF: C172H265N43O51

MW: 3751.202

EINECS:  810-818-7

Specification​: 99% min Liraglutide 

Sample: Liraglutide Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Peptide Liraglutide Powder Liraglutide Raw Materials Liraglutide API manufacturers, High Purity Peptide Powder Liraglutide, Liraglutide Raw Powder CAS 204656-20-2.

Liraglutide Raw Materials has many effects such as promoting pancreatic islet cell regeneration, lowering blood glucose, reducing body weight and protecting the cardiovascular system,

Liraglutide Raw Powder is used in the treatment of type 2 diabetes mellitus under the trade name Victoza, and is used in the treatment of chronic obesity under the trade name Saxenda, and is used as a supplement to dietary control and physical exercise. Uses and functions of Liraglutide Raw Powder

Uses and functions of Liraglutide Raw Powder.

1. Liraglutide Raw Powder has the following pharmacological effects:
2. Peptide Liraglutide Powder has a protective effect on pancreatic β-cells.
3. Liraglutide Raw Materials Lowering effect on body mass
4. Cardiovascular effects of Liraglutide
5. Liraglutide Raw Materials Protective effect on liver
6. Therapeutic Effects on Alzheimer's Disease (AD)
7. 

Pharmacological Effects of Liraglutide Powder.

Liraglutide Powder is like endogenous GLP-1, binding and activating the GLP-1 receptor, a cell surface receptor that activates adenylate cyclase through excitatory G-protein Gs coupling.

On the other hand, absorption into the blood increases binding to plasma albumin, forming a slow-release reservoir that temporarily avoids contact with endogenous enzymes and slows release, resulting in prolonged in vivo absorption and distribution, and a significantly longer half-life than natural GLP-1.

Endogenous GLP-1 has a half-life of 1.5-2 min and is readily degraded by two widely available endogenous enzymes, dipeptidyl peptidase 4 (DPP-4) and neutral peptide chain endonuclease (NEP). Compared to natural GLP-1, liraglutide is more stable, with a plasma half-life after subcutaneous administration of 13 h.

This change in half-life is attributed to structural modifications of Liraglutide Raw Powder, whereby the hydrophobicity of palmitic acid on the one hand, due to the presence of fatty acid side-chains, self-conjugates into a heptamer, which slows down the absorption at the site of subcutaneous injection;

Production method of Liraglutide Powder.

Liraglutide Powder, as a novel long-acting GLP-1 analogue, has 97% sequence homology with human GLP-1, which binds to and activates the GLP-1 receptor, which is the target of natural GLP-1, an endogenous enteric insulinotropic hormone that promotes pancreatic islet β-cell proliferation and differentiation, and markedly protects and improve the function of pancreatic β-cells.

Meanwhile, Liraglutide Raw Powder is simple and convenient to apply, and it can provide 24h blood glucose control once a day with low risk of hypoglycaemia, so it is expected to become a new type of drug for the treatment of type 2 diabetes mellitus.